Free tool
FAERS Monitor: Miebo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216675 or its brand name (Miebo, Perfluorohexyloctane). Reports on generic versions are filed under their own applications.
Reports
2,325
Serious
761
33% of reports
Hospitalization
210
Death reported
166
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- inappropriate schedule of product administration328
- eye pain307
- eye irritation297
- vision blurred275
- product use issue240
- product delivery mechanism issue201
- drug ineffective177
- circumstance or information capable of leading to medication error170
- product use complaint164
- ocular hyperaemia159
- death158
- dry eye154
- accidental exposure to product134
- exposure via skin contact133
- headache124
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 10 |
| 2023 | 66 |
| 2024 | 398 |
| 2025 | 926 |
| 2026 | 922 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,834 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product delivery mechanism issueSignal | 201 | 351.3 | 306.9 | 67,264 |
| product use complaintSignal | 164 | 95.2 | 82.0 | 15,038 |
| eye painSignal | 307 | 49.5 | 44.6 | 14,496 |
| eye irritationSignal | 297 | 46.9 | 42.2 | 13,268 |
| exposure via skin contactSignal | 133 | 46.7 | 39.5 | 5,874 |
| circumstance or information capable of leading to medication errorSignal | 170 | 45.8 | 39.6 | 7,372 |
| ocular hyperaemiaSignal | 159 | 30.4 | 26.2 | 4,488 |
| dry eyeSignal | 154 | 28.0 | 24.0 | 3,979 |
| vision blurredSignal | 275 | 18.2 | 16.2 | 4,460 |
| inappropriate schedule of product administrationSignal | 328 | 16.5 | 14.9 | 4,790 |
| accidental exposure to productSignal | 134 | 11.8 | 10.0 | 1,315 |
| product use issueSignal | 240 | 11.6 | 10.3 | 2,324 |
| headache | 124 | 1.8 | 1.5 | 44 |
| death | 158 | 1.7 | 1.4 | 42 |
| drug ineffective | 177 | 1.2 | 1.1 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.